Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

All GLG News Analyses Filed Under: Oncology

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

Eric Whitman, Medical Director, Office of Grants and Research

Eric WhitmanMedical Director, Office of Grants and ResearchATLANTIC HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Synta Melanoma study stopped due to unspecified safety concerns

March 20, 2009

Synta Suspends Elesclomol SYMMETRY Trial in Metastatic Melanoma | www.businesswire.com

A leading Phase III trial in metastatic melanoma was stopped due to safety concerns raised by the independent data safety monitoring board (DSMB). Synta Pharmaceuticals was testing its lead candidate drug, Elesclomol, in a double blind randomized trial in combination with Taxol for front-line treatment of Stage IV melanoma patients.

Herceptin for Gastric Cancer? Roche Says, "Yes!"

March 19, 2009

GLG Expert Contributor

UPDATE 1-Roche's Herceptin prolongs stomach cancer survival | www.reuters.com

Herceptin is an established biologic drug with proven efficacy in some -about 20% - breast cancer tumors.  The teaser for this study suggests that Herceptin + chemo "significantly" prolongs survival compared to chemo alone for advanced gastric cancer. 

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Alimta potential In India

February 27, 2009

Intas Biopharma to market Pemetrexed in India soon | www.pharmabiz.com

Alimta has been approved as upfront treatemnt of NSCLCA with platinum Alimta approved US as  single agent salvage treatment NSCLCa Market share IN US hsa been crowded out by other platinum combinations

A timely and modern alternative to the squeeze women dread.

February 24, 2009

GLG Expert Contributor

Innovation for Women’s Health – the new MRI breast scanner from Siemens | www.innovations-report.de

Accuracy, simplicity and freedom for the claustrophobic make this an advancement in medical imaging so needed for today.  Women's fears have always plagued the early recognition of breast cancer and this offers them a substantial answer to these concerns.

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

tarceva adds to avastin but avastin doesn't add to tarceva?

February 17, 2009

OSI, Genentech Say Cancer Drug’s Benefits Ends Trial (Update2) | www.bloomberg.com

Beta lung demonstrated no benefit of adding avastin to tarceva as second line advanced lung cancer therapy Atals trial demonstrates adding tarceva to avastin after chemo in advanced lung cancer does benefit

Systemic mRNA therapy for liver cancer cancer is new direction

February 16, 2009

GLG Expert Contributor

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer | www.pipelinereview.com

 Systemic micro RNA therapy has great future  for liver cancer cancer. Small molecule probes as mRNA inhibitors will open new avenue for cancer therapy basically to liver cancer.

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

The nth proof...

February 16, 2009

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer | www.ncbi.nlm.nih.gov

The trial showed that the addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. This is a new demonstration that the association of anti-EGFR and anti-angiogenic drugs is toxic and ineffective. 

Panitumumab (and thus Erbitux): The Good, the Bad and the Ugly

February 9, 2009

GLG Expert Contributor

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer | www.ncbi.nlm.nih.gov

Panitumumab (Amgen) plus Avastin (Genentech) and chemo performs worse than Avastin and chemo alone in CRC. This is on top of data that Erbitux [GSK,Merck, Imclone] (EGFR inhibitor like Panit...) combined with Avastin is deleterious to CRC patients health. (see a prior blog)

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Are nexavar prescriptions increasing?

February 9, 2009

Nexavar® Effective for Hepatocellular Carcinoma in Asians | patient.cancerconsultants.com

Nexavar confirms its efficacy for hepatocellular carcinoma also in the Asian population.

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

More may or may not be better in colorectal cancer

February 6, 2009

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | nejm.highwire.org

Recent trial such as PACE and CAIRO imply combo biologics are not helpful Is it likely this will hold true in future situations?

Previous Page : 12345678910Next41 to 50 of 900

Request a News Analysis

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Leading institutions connect with members of the Healthcare councils through GLG

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading
mutual funds
15 of the leading 20
global banks
7 of the leading 10
global private equity firms
5 of the leading 10
AmLaw firms
Fortune 500® Companies
in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software

Most Popular Oncology News